Progyny/$PGNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Ticker
$PGNY
Sector
Primary listing
Employees
678
Headquarters
Website
Progyny Metrics
BasicAdvanced
$1.9B
37.91
$0.58
1.32
-
Price and volume
Market cap
$1.9B
Beta
1.32
52-week high
$26.76
52-week low
$13.39
Average daily volume
1.1M
Financial strength
Current ratio
2.697
Quick ratio
2.617
Long term debt to equity
4.952
Total debt to equity
4.952
Profitability
EBITDA (TTM)
80.791
Gross margin (TTM)
22.34%
Net profit margin (TTM)
4.28%
Operating margin (TTM)
6.18%
Effective tax rate (TTM)
40.47%
Revenue per employee (TTM)
$1,830,000
Management effectiveness
Return on assets (TTM)
6.57%
Return on equity (TTM)
10.94%
Valuation
Price to earnings (TTM)
37.911
Price to revenue (TTM)
1.545
Price to book
3.67
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
10.091
Free cash flow yield (TTM)
9.91%
Free cash flow per share (TTM)
2.193
Growth
Revenue change (TTM)
9.62%
Earnings per share change (TTM)
-7.30%
3-year revenue growth (CAGR)
26.26%
3-year earnings per share growth (CAGR)
8.19%
What the Analysts think about Progyny
Analyst ratings (Buy, Hold, Sell) for Progyny stock.
Bulls say / Bears say
Q1 2025 revenue reached a record $324.0 million, up 16.5% year-over-year and 19% when excluding $31.3 million from a non-renewing large client, highlighting robust demand for Progyny’s fertility and family building solutions (GlobeNewswire).
Progyny expanded its client base to 532 fertility and family building clients as of March 31, 2025, up from 451 a year earlier, demonstrating strong market penetration and sales momentum (Nasdaq).
With $256.1 million in cash and cash equivalents, no debt, and approximately $330.6 million in working capital at quarter-end, Progyny maintains a solid balance sheet to support growth initiatives and navigate macroeconomic uncertainty (Nasdaq).
The non-renewal of a major client's services agreement, which accounted for approximately $31.3 million of Q1 revenue and represented about 12% of trailing quarterly revenue, exposes Progyny to a potential revenue cliff as the extended transition care agreement winds down by mid-2025 (GlobeNewswire).
Despite 16.5% revenue growth, Q1 net income remained flat at $15.1 million versus $16.9 million a year earlier, as higher tax provisions driven by discrete equity compensation impacts eroded bottom-line growth (GlobeNewswire).
Adjusted EBITDA margin narrowed to 17.8% from 18.1% year-over-year, reflecting increased investments in platform expansion and recent acquisitions that are pressuring operating efficiency (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Progyny Financial Performance
Revenues and expenses
Progyny Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Progyny stock?
Progyny (PGNY) has a market cap of $1.9B as of September 16, 2025.
What is the P/E ratio for Progyny stock?
The price to earnings (P/E) ratio for Progyny (PGNY) stock is 37.91 as of September 16, 2025.
Does Progyny stock pay dividends?
No, Progyny (PGNY) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Progyny dividend payment date?
Progyny (PGNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Progyny?
Progyny (PGNY) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.